

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10560329
	<b>Filing Date</b>		2005-12-10
	<b>First Named Inventor</b>	Kim	
	<b>Art Unit</b>	1649	
	<b>Examiner Name</b>	Stacey Nee MACFARLANE	
<b>Attorney Docket Number</b>		4240-138	

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								<a href="#">Remove</a>
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS			<a href="#">Remove</a>
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ts

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560329
Filing Date	2005-12-10
First Named Inventor	Kim
Art Unit	1649
Examiner Name	Stacey Nee MACFARLANE
Attorney Docket Number	4240-138

1	BERNSTEIN, EMILY, ET AL., "Role for a bidentate ribonuclease in the initiation step of RNA interference", "Nature", January 18, 2001, Page(s) 363-366, Volume 409	<input type="checkbox"/>
2	DERYONCK, RIK, ET AL., "Smad-dependent and smad-independent pathways in TGF-beta family signalling", "Nature", October 9, 2003, Page(s) 577-584, Volume 425	<input type="checkbox"/>
3	NAGAHARA, HIKARU, ET AL., "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kip1 induces cell migration", "Nature Medicine", December 1998, Page(s) 1449-1452, Volume 4, Number 12	<input type="checkbox"/>
4	RUPPERT, RAINER, ET AL., "Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity", "Eur. J. Biochem.", 1996, Page(s) 395-302, Volume 237	<input type="checkbox"/>
5	SCHEUFLER, CLEMENS, ET AL., "Crystal structure of human bone morphogenetic protein-2 at 2.7 Å resolution", "J. Mol. Bio.", 1999, Page(s) 103-115, Volume 287	<input type="checkbox"/>
6	SCHWARZE, STEVEN R., ET AL., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse", "Science", September 3, 1999, Page(s) 1569-1572, Volume 285, Number 5433	<input type="checkbox"/>
7	SCHWARZE, STEVEN R., ET AL., "Protein transduction: unrestricted delivery into all cells?", "Trends in Cell Biology", July 2000, Page(s) 290-295, Volume 10	<input type="checkbox"/>
8	STORM, ELAINE E., ET AL., "Limb alterations in brachypodism mice due to mutations in a new member of the TGFbeta-superfamily", "Nature", April 14, 1994, Page(s) 639-643, Volume 368	<input type="checkbox"/>
9	THOMAS, GARY, "Furin at the cutting edge: from protein traffic to embryogenesis and disease", "Nature Reviews Molecular Cell Biology", October 2002, Page(s) 753-766, Volume 3	<input type="checkbox"/>
10	VINALL, RUTH L., ET AL., "The effect of BMP on the expression of cytoskeletal proteins and its potential relevance", "The Journal of Bone and Joint Surgery", 2001, Page(s) (S1) 63-69, Volume 83A, Number 1	<input type="checkbox"/>
11	WADIA, JEHANGIR S., ET AL., "Modulation of cellular function by TAT mediated transduction of full length proteins", "Current Protein and Peptide Science", 2003, Page(s) 97-104, Volume 4	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560329
Filing Date	2005-12-10
First Named Inventor	Kim
Art Unit	1649
Examiner Name	Stacey Nee MACFARLANE
Attorney Docket Number	4240-138

12	YAMASHITA, HIDETOSHI, ET AL., "Growth/differentiation factor-5 induces angiogenesis in vivo", "Experimental Cell Research", 1997, Page(s) 218-226, Volume 235	<input type="checkbox"/>
13	ZEISBERG, MICHAEL, ET AL., "BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury", "Nature Medicine", July 2003, Page(s) 964-968, Volume 9, Number 7	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.